Allink Biotherapeutics, Inc. (AllinkBio), a clinical-stage biotechnology company, has raised US$47 million after successfully completing the extension rounds of its Series A funding.
The funding round was led by existing investor Legend Capital and new investor Meituan Long-Z Investment, with participation from several other new and returning investors, including Lanchi Ventures, Yuanbio Venture Capital, 5Y Capital, Lapam Capital, and Runzhang Venture Capital. AllinkBio focuses on developing advanced antibody-based therapies for cancer and immune-related diseases.
The Series A extension funding will be used to move forward with global clinical trials for AllinkBio’s two main drug programs. Both programs have shown strong potential and offer clear advantages over existing treatments.
ALK201, which targets FGFR2b, has shown promising results across different types of tumors with a good safety profile. This supports its development as a key treatment for solid tumors that overexpress FGFR2b. At the same time, early clinical results for ALK202, an EGFR/cMET dual-target ADC, suggest it could become an important treatment option for non-small cell lung cancer. The company is also expanding studies into more tumor types and patient groups based on specific biomarkers.
AllinkBio is developing both drugs using a biomarker-guided approach to prove effectiveness across many solid tumors. In the near future, the company plans to start combination therapy studies to test these drugs in a wider group of patients. These efforts will help prepare ALK201 and ALK202 for large, late-stage trials and strengthen their positions in their target cancer indications.
“We sincerely appreciate the decisive and continued support from our investors within such a short timeframe,” said Hui Feng, Ph.D., Founder and Chief Executive Officer of AllinkBio. “With this support, we are moving forward with a clear clinical roadmap to accelerate our lead programs. Beyond the two leading programs, our discovery engine is fully activated, poised to deliver new wave of innovative drug candidates that will unlock further value in the foreseeable future .”
“Our continued support is rooted in our confidence in the AllinkBio team’s efficient execution and their robust development strategy,” said Tan Hong, Managing Director at Legend Capital. “The rapid clinical advancement of their two competitive lead assets is already serving as a strong validation of the company’s ADC platform and presenting significant value. We look forward to the near-term clinical readouts and seeing more innovative programs emerge from their discovery platforms.”
“The AllinkBio team pairs an international mindset with best-in-class execution, setting a remarkable pace in the ADC space,” said Xuejing Guo, Managing Director and Head of Healthcare at Meituan Long-Z Investment. “We are deeply impressed by the potential of their technology platform and are excited to help the team translate these original innovations into global impact, ultimately delivering life-changing therapies to patients worldwide.”
Founded in 2023, AllinkBio is a clinical-stage biotechnology company that focuses on discovering and developing advanced antibody-drug conjugates (ADCs) and multi-specific antibody treatments for cancer and immune-related diseases.
By using strong research capabilities and efficient development platforms, the company has quickly moved two ADC candidates into global Phase I clinical trials. AllinkBio aims to continue innovating in ADC and multi-specific antibody therapies to improve and transform the lives of patients worldwide.
Read More- Propagate India Appoints Parikshit Bhattacharya as Chief Creative Officer
